Comparative Pharmacology
Head-to-head clinical analysis: INCIVEK versus SYLATRON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INCIVEK versus SYLATRON.
INCIVEK vs SYLATRON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibitor of the HCV NS3/4A serine protease, preventing cleavage of the HCV polyprotein, thereby inhibiting viral replication.
Peginterferon alfa-2b binds to type I interferon receptors, activating JAK-STAT signaling and inducing expression of antiviral, antiproliferative, and immunomodulatory proteins.
Incivek (telaprevir) is administered orally at a dose of 750 mg (two 375 mg tablets) three times daily (every 7-9 hours) with food (not low-fat).
200 mcg/kg subcutaneously once weekly for 1 year in combination with oral ribavirin.
None Documented
None Documented
Terminal elimination half-life ranges from 4 to 13 hours (mean ~7 hours) in healthy volunteers; prolonged to 10-20 hours in HCV-infected patients.
Terminal elimination half-life is approximately 40 hours (range 27-60 hours) following subcutaneous administration. This prolonged half-life supports once-weekly dosing.
Approximately 91% of the radiolabeled dose is recovered in feces (79% as unchanged drug) and 9% in urine (1% as unchanged drug).
Renal clearance is the primary route of elimination for peginterferon alfa-2b. Approximately 30% of the dose is excreted unchanged in urine, with the remainder metabolized and excreted via bile/feces.
Category C
Category C
Antiviral
Interferon Antineoplastic/Antiviral